Skip to main content
Top
Published in: Medical Oncology 2/2008

01-06-2008 | Original Paper

E1A inhibits the proliferation of human cervical cancer cells (HeLa cells) by apoptosis induction through activation of HER-2/Neu/Caspase-3 pathway

Authors: Liangfang Shen, Shan Zeng, Jia Chen, Meizuo Zhong, Huixiang Yang, Ruojing Yao, Hong Shen

Published in: Medical Oncology | Issue 2/2008

Login to get access

Abstract

Objective    This study is to investigate the inhibitory effect of E1A gene on the cell proliferation of HeLa cells and its mechanism related to apoptosis. Methods    MTT assay and soft agar colony formation assay were employed to justify the inhibition activity of E1A on the proliferation of HeLa cells transfected with E1A gene. Western Blot, RT-PCR and Real-time quantitative RT-PCR were used to detect the gene expression of E1A, HER-2/Neu and Caspase-3 in HeLa cells, respectively. The Caspase-3 activity was monitored by ApoAlert Caspase-3 Assay. The redistribution of cell cycles and apoptosis of HeLa cells regulated by E1A expression were evaluated by flow cytometry. Results    E1A expression significantly inhibits the cell proliferation and anchorage-independent cell growth of HeLa, with the respective highest inhibition rate of 40.7% and 43.4% (P < 0.01). HER-2/Neu expression in HeLa was significantly down-regulated by E1A, while the protein expression and activity of Caspase-3 was up-regulated by E1A expression. Flow cytometry revealed that E1A transfection in HeLa increased the cell number at G1 stage and simultaneously decreased the cell number at S stage. E1A transfection induced 8.71% of HeLa cells at apoptosis status. Conclusions    E1A significantly inhibits the cell proliferation of HeLa by the apoptosis induction through HER-2/Neu/Caspase-3 pathway. These results encourage us to continue an in-vivo study and preclinical development of LPD-E1A as a novel gene therapeutic agent for human cervical cancer.
Literature
1.
go back to reference Jemal A, Thomas A, Murray T, et al.Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47. Jemal A, Thomas A, Murray T, et al.Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47.
2.
go back to reference Dreyer G, Snyman LC, Mouton A, et al. Management of recurrent cervical cancer. Best Pract Res Clin Obstet Gynaecol 2005;19:631–44.PubMedCrossRef Dreyer G, Snyman LC, Mouton A, et al. Management of recurrent cervical cancer. Best Pract Res Clin Obstet Gynaecol 2005;19:631–44.PubMedCrossRef
3.
go back to reference Quist SR, Wang-Gohrke S, Kohler T, et al. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Cancer Gene Ther 2004;11:547–54.PubMedCrossRef Quist SR, Wang-Gohrke S, Kohler T, et al. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Cancer Gene Ther 2004;11:547–54.PubMedCrossRef
4.
go back to reference Frisch SM. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc Natl Acad Sci U S A 1991;88:9077–81.PubMedCrossRef Frisch SM. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc Natl Acad Sci U S A 1991;88:9077–81.PubMedCrossRef
5.
go back to reference Li Z, Day CP, Yang JY, et al. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res 2004;64:9080–5.PubMedCrossRef Li Z, Day CP, Yang JY, et al. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res 2004;64:9080–5.PubMedCrossRef
6.
go back to reference Chen H, Hung MC. Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene. J Biol Chem 1997;272:6101–4.PubMedCrossRef Chen H, Hung MC. Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene. J Biol Chem 1997;272:6101–4.PubMedCrossRef
7.
go back to reference Sharma A, Pratap M, Sawhney VM, et al. Frequent amplification of C-erbB2 (HER-2/Neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections. Oncology 1999;56:83–7.PubMedCrossRef Sharma A, Pratap M, Sawhney VM, et al. Frequent amplification of C-erbB2 (HER-2/Neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections. Oncology 1999;56:83–7.PubMedCrossRef
8.
go back to reference Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, et al. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006;32:180–90.PubMedCrossRef Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, et al. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006;32:180–90.PubMedCrossRef
9.
go back to reference Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, et al. HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004;4:59.PubMedCrossRef Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, et al. HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004;4:59.PubMedCrossRef
10.
go back to reference Ueno NT, Bartholomeusz C, Xia W, et al. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 2002;62:6712–6.PubMed Ueno NT, Bartholomeusz C, Xia W, et al. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 2002;62:6712–6.PubMed
11.
go back to reference Li S, Rizzo MA, Bhattacharya S, et al. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998;5:930–7.PubMedCrossRef Li S, Rizzo MA, Bhattacharya S, et al. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998;5:930–7.PubMedCrossRef
12.
go back to reference Shen H, Huang G, Hadi M, et al. Transforming growth factor-beta1 downregulation of Smad1 gene expression in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2003;285:G539–46.PubMed Shen H, Huang G, Hadi M, et al. Transforming growth factor-beta1 downregulation of Smad1 gene expression in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2003;285:G539–46.PubMed
13.
go back to reference Shen H, Zhang M, Minuk GY, et al. Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation. BMC Cell Biol 2002;3:9.PubMedCrossRef Shen H, Zhang M, Minuk GY, et al. Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation. BMC Cell Biol 2002;3:9.PubMedCrossRef
14.
go back to reference Chun YJ, Park IC, Park MJ, et al. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3). FEBS Lett 2002;519:195–200.PubMedCrossRef Chun YJ, Park IC, Park MJ, et al. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3). FEBS Lett 2002;519:195–200.PubMedCrossRef
15.
go back to reference Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001;19:3422–33.PubMed Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001;19:3422–33.PubMed
16.
go back to reference Madhusudan S, Tamir A, Bates N, et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004;10:2986–96.PubMedCrossRef Madhusudan S, Tamir A, Bates N, et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004;10:2986–96.PubMedCrossRef
17.
go back to reference Zhou Z, Zhou RR, Guan H, et al. E1A gene therapy inhibits angiogenesis in a Ewing’s sarcoma animal model. Mol Cancer Ther 2003;2:1313–9.PubMed Zhou Z, Zhou RR, Guan H, et al. E1A gene therapy inhibits angiogenesis in a Ewing’s sarcoma animal model. Mol Cancer Ther 2003;2:1313–9.PubMed
18.
go back to reference Li X, Zhang YP, Kim HS, et al. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Res 2005;65:1941–51.PubMedCrossRef Li X, Zhang YP, Kim HS, et al. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Res 2005;65:1941–51.PubMedCrossRef
19.
go back to reference Ueno NT, Bartholomeusz C, Herrmann JL, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000;6:250–9.PubMed Ueno NT, Bartholomeusz C, Herrmann JL, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000;6:250–9.PubMed
20.
go back to reference Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998;391:96–9.PubMedCrossRef Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998;391:96–9.PubMedCrossRef
21.
go back to reference Shimizu M, Deguchi A, Lim JT, et al. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005;11:2735–46.PubMedCrossRef Shimizu M, Deguchi A, Lim JT, et al. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005;11:2735–46.PubMedCrossRef
22.
go back to reference Hou R, Zhou QL, Wang BX, et al. Diosgenin induces apoptosis in HeLa cells via activation of caspase pathway. Acta Pharmacol Sin 2004;25:1077–82.PubMed Hou R, Zhou QL, Wang BX, et al. Diosgenin induces apoptosis in HeLa cells via activation of caspase pathway. Acta Pharmacol Sin 2004;25:1077–82.PubMed
23.
go back to reference Huang YW, Li MD, Wu QL, et al. [Expression and clinical significance of p53 and c-erbB2 in geriatric women with cervical carcinoma]. Ai Zheng 2002;21:297–300.PubMed Huang YW, Li MD, Wu QL, et al. [Expression and clinical significance of p53 and c-erbB2 in geriatric women with cervical carcinoma]. Ai Zheng 2002;21:297–300.PubMed
24.
go back to reference Chang JY, Xia W, Shao R, et al. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 1997;14:561–8.PubMedCrossRef Chang JY, Xia W, Shao R, et al. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 1997;14:561–8.PubMedCrossRef
26.
go back to reference Jiang Y, Saavedra HI, Holloway MP, et al. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 2004;279:40511–20.PubMedCrossRef Jiang Y, Saavedra HI, Holloway MP, et al. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 2004;279:40511–20.PubMedCrossRef
27.
go back to reference Wang HG, Rikitake Y, Carter MC, et al. Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth. J Virol 1993;67:476–88.PubMed Wang HG, Rikitake Y, Carter MC, et al. Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth. J Virol 1993;67:476–88.PubMed
28.
go back to reference Mymryk JS, Shire K, Bayley ST. Induction of apoptosis by adenovirus type 5 E1A in rat cells requires a proliferation block. Oncogene 1994;9:1187–93.PubMed Mymryk JS, Shire K, Bayley ST. Induction of apoptosis by adenovirus type 5 E1A in rat cells requires a proliferation block. Oncogene 1994;9:1187–93.PubMed
29.
go back to reference Chiou SK, White E. p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. J Virol 1997;71:3515–25.PubMed Chiou SK, White E. p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. J Virol 1997;71:3515–25.PubMed
30.
go back to reference Flinterman MB, Mymryk JS, Klanrit P, et al. p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing. Oncogene 2007. doi: 10.1038/sj.onc.1210497. Flinterman MB, Mymryk JS, Klanrit P, et al. p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing. Oncogene 2007. doi: 10.​1038/​sj.​onc.​1210497.
Metadata
Title
E1A inhibits the proliferation of human cervical cancer cells (HeLa cells) by apoptosis induction through activation of HER-2/Neu/Caspase-3 pathway
Authors
Liangfang Shen
Shan Zeng
Jia Chen
Meizuo Zhong
Huixiang Yang
Ruojing Yao
Hong Shen
Publication date
01-06-2008
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 2/2008
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-007-9007-1

Other articles of this Issue 2/2008

Medical Oncology 2/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.